The therapeutic use of cannabis sativa l. as a treatment option for orofacial pain and disorders caused in the temporomandibular joint
DOI:
https://doi.org/10.55892/jrg.v8i18.1802Keywords:
Temporomandibular Joint Disorders, Cannabis, Musculoskeletal Diseases, Facial Pain and EndocannabinoidsAbstract
Cannabis sativa L. is a plant rich in several cannabinoids, many of which have significant therapeutic properties. Among these compounds, cannabidiol (CBD) and tetrahydrocannabinol (THC) stand out, which have shown potential in several treatments. In the field of dentistry, the adequate and supported use of these cannabinoids can be incorporated into the pharmacological routine for pain management, providing relief and substantial benefits to patients suffering from orofacial pain and temporomandibular dysfunction (TMD). In view of this, this study aims, through a literature review, to highlight the importance of Cannabis sativa-based medications in the relief of orofacial pain during dental treatments. Studies show that the use of medicinal Cannabis, especially CBD and THC, has shown to be a promising alternative for the treatment of chronic orofacial pain, due to its analgesic and anti-inflammatory properties. It is important to note that this plant is extremely diverse, containing more than 500 components, among which cannabinol (CBN) and cannabigerol (CBG) also stand out, both recognized for their great therapeutic potential, which indicates their application in various treatments. It is worth mentioning that the combination of CBD with THC enhances the effect of the drugs (CBD, CBG and CBN), resulting in a more efficient and targeted treatment, reducing the harmful effects when compared to the use of THC alone. Therefore, dentists must be aware of the dosage and the correct therapeutic indication, considering factors such as the individuality of the patient, the duration and intensity of the pain, and the interaction of Cannabis with other medications used in dental treatment. Furthermore, it is essential that the professional evaluates the therapeutic efficacy and is aware of possible adverse effects. It is known that the management of orofacial pain is one of the most common challenges faced in dental practice, and the use of Cannabis sativa appears to be an effective approach that can complement or enhance conventional treatments, or even replace them in certain cases. However, despite the promising results, further studies are still needed to ensure the safety of long-term use, in addition to investigating possible adverse effects and drug interactions with other drugs. Mastering this knowledge by the dentist is essential for safe and effective clinical application.
Downloads
References
Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). (2023). Resolução da Diretoria Colegiada no 355. Brasília.
Brito, M. S., Carvalho, V. M., & Gandra, M. (2017). Mães pela cannabis medicinal em um Brasil aterrorizado entre luzes e fantasmas. Fórum Sociológico, 2(30), 5766–78.
Clayton, P., Hill, M., Bogoda, N., Subah, S., & Venkatesh, R. (2021). Palmitoylethanolamide: a natural compound for health management. International Journal of Molecular Sciences, 22(10), 5305. https://doi.org/10.3390/ijms22105305
Ettlin, D. A., et al. (2016). Design, construção e implementação técnica de uma avaliação de sintomas interdisciplinar baseada na web (WISE): Uma proposta heurística para dor orofacial e distúrbios temporomandibulares. O Jornal da Dor de Cabeça e Dor, 17(1).
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D'Agnone, O., Schecter, D., ... & Cyr, C. (2020). Safety considerations in cannabinoid-based medicine. International Journal of General Medicine, 13, 1317–1333. https://doi.org/10.2147/IJGM.S275049
Ibrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., ... & Malan, T. P. Jr. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS. Proceedings of the National Academy of Sciences, 100(18), 10529–33.
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiological Reviews, 89(1), 309–80. https://doi.org/10.1152/physrev.00019.2008
Legare, C. A., et al. (2022). Potencial terapêutico da cannabis, cannabidiol e produtos farmacêuticos à base de canabinoides. Farmacologia, 107(3–4), 131–149.
Mlost, J., et al. (2020). Canabidiol para o tratamento da dor: Foco na farmacologia e mecanismo de ação. Revista Internacional de Ciências Moleculares, 21(22), 8870. https://doi.org/10.3390/ijms21228870
National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press.
Okeson, J. P., & De Leeuw, R. (2014). Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dental Clinics of North America.
Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389–462. https://doi.org/10.1124/pr.58.3.2
Pertwee, R. G. (2005). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS Journal, 7(3), E625–54.
Rice, A. S. (2001). Cannabinoids and pain. Current Opinion in Investigational Drugs (London, England: 2000), 2(3), 399–414.
Russo, E. B., Cuttler, C., Cooper, Z. D., Stueber, A., Whiteley, V. L., Sexton, M. (2021). Survey of patients employing cannabigerol-predominant cannabis preparations: Perceived medical effects, adverse events, and withdrawal symptoms. Cannabis and Cannabinoid Research, 7(5), 706–16. https://doi.org/10.1089/can.2021.0004
Takatori, J. (1996). Medicinal plants of Japan. Hirokawa Publishing Company.
Tambeli, C. H., Martins, G. A., Barbosa, S. L., & Machado, T. T. (2023). Integrative approach to the therapeutic use of cannabis for orofacial pain. Brazilian Journal of Pain, 6(Suppl 1), S49–53. https://doi.org/10.5935/2595-0118.20230026
Türp, J. C. (2017). Failure in chronic pain therapy across the disciplines: Consequences for the management of orofacial pain. Schmerztherapie, 9(3), 197–208.
Valesan, L. F., Da-Cas, C. D., Réus, J. C., Denardin, A. C. S., Garanhani, R. R., Bonotto, D., ... & de Souza, B. D. M. (2021). Prevalência de disfunções da articulação temporomandibular: Uma revisão sistemática e meta-análise. Clinical Oral Investigations, 25(2), 441–453. https://doi.org/10.1007/s00784-020-03710-w
VanDolah, H. J., Bauer, B. A., & Mauck, K. F. (2019). Clinicians’ guide to cannabidiol and hemp oils. Mayo Clinic Proceedings, 94(9), 1840–51. https://doi.org/10.1016/j.mayocp.2019.01.003
Wong, H., Hossain, S., & Cairns, B. E. (2017). Delta‐9‐tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation. European Journal of Pain, 21(10), 1732–42. https://doi.org/10.1002/ejp.1075
